Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Evaluation of the use of static and dynamic models to predict drug-drug interaction and its associated variability: impact on drug discovery and early development.

Peters SA, Schroeder PE, Giri N, Dolgos H.

Drug Metab Dispos. 2012 Aug;40(8):1495-507. doi: 10.1124/dmd.112.044602. Epub 2012 May 7.

PMID:
22566536
2.

The dihydroorotase inhibitor 5-aminoorotic acid inhibits the metabolism in the rat of the cardioprotective drug dexrazoxane and its one-ring open metabolites.

Schroeder PE, Patel D, Hasinoff BB.

Drug Metab Dispos. 2008 Sep;36(9):1780-5. doi: 10.1124/dmd.108.021626. Epub 2008 May 30.

PMID:
18515330
3.

Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.

Schroeder PE, Hasinoff BB.

Drug Metab Dispos. 2005 Sep;33(9):1367-72. Epub 2005 Jun 24.

PMID:
15980099
4.

Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.

Schroeder PE, Wang GQ, Burczynski FJ, Hasinoff BB.

Drug Metab Dispos. 2005 Jun;33(6):719-25. Epub 2005 Mar 11.

PMID:
15764716
5.

Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent.

Schroeder PE, Hofland KF, Jensen PB, Sehested M, Langer SW, Hasinoff BB.

Cancer Chemother Pharmacol. 2004 Jan;53(1):91-3. Epub 2003 Oct 22.

PMID:
14574459
6.
7.

Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.

Schroeder PE, Jensen PB, Sehested M, Hofland KF, Langer SW, Hasinoff BB.

Cancer Chemother Pharmacol. 2003 Aug;52(2):167-74. Epub 2003 May 15.

PMID:
12750840
8.

The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.

Schroeder PE, Hasinoff BB.

Cancer Chemother Pharmacol. 2002 Dec;50(6):509-13. Epub 2002 Oct 31.

PMID:
12451479
9.

Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187).

Schroeder PE, Davidson JN, Hasinoff BB.

Drug Metab Dispos. 2002 Dec;30(12):1431-5.

PMID:
12433815
10.

Alcoholic myopathy and myoglobinuric nephrosis.

Powers R, Thompson CE, Schroeder PE.

Mich Med. 1971 Dec;70(31):1111-4. No abstract available.

PMID:
5118965
11.

Myocardial infarction in an industrial city.

BAREIS RJ, SCHROEDER PE, DREWYER GE.

J Mich State Med Soc. 1957 Dec;56(12):1561-5 passim. No abstract available.

PMID:
13492004

Supplemental Content

Loading ...
Support Center